Asterias Biotherapeutics (AST) Reports Q2 Loss of $0.10

Asterias Biotherapeutics (NYSE: AST) reported Q2 EPS of ($0.10), versus ($0.10) reported last year. Revenue for the quarter came in at $0 versus the consensus estimate of $580 thousand.

Cash and cash equivalents were $15.6 million as of June 30, 2015, compared to $3.1 million as of December 31, 2014.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Celanese to sell 19% Nutrinova stake to Mitsui for $152 million
• Morgan Stanley Downgrades Nordea Bank Abp (NDA:SS) (NRDBY) to Equalweight